# Immunogenicity and Safety of Sabin-IPV Replacement Vaccination

> **NCT04051736** · PHASE4 · COMPLETED · sponsor: **China National Biotec Group Company Limited** · enrollment: 360 (actual)

## Conditions studied

- Vaccination

## Interventions

- **BIOLOGICAL:** Inactivated Polio Vaccine

## Key facts

- **NCT ID:** NCT04051736
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2018-12-28
- **Final completion:** 2020-08-31
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2020-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051736, "Immunogenicity and Safety of Sabin-IPV Replacement Vaccination". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04051736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*